EDEN RESEARCH PLC

Registration Form • Aug 28, 2013

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 5793M

Eden Research plc

28 August 2013

28 August 2013

Eden Research Plc

("Eden" or "Company")

Notice of Allowance for Philippines patent

Eden Research plc (AIM: EDEN), the AIM listed terpene and encapsulation development company, announces that the Intellectual Property Office of the Philippines has issued a Notice of Allowance for its platform encapsulation technology.

The patent covers the Company's core technology, specifically "compositions containing a hollow glucan particle or a cell wall particle encapsulating a terpene component, methods of making and using them."

The encapsulation system is owned outright by Eden and is already granted in Europe, New Zealand, Australia, China, Mexico, Singapore and South Africa. The benefit of having the patent formally granted is that it gives the security of full patent protection to existing and prospective licensees in the Philippines.

Clive Newitt, Managing Director of Eden comments: "We are delighted to announce this Notice of Allowance which further strengthens our intellectual property portfolio. The success of our application validates the uniqueness of our technology and its patentability. It also ensures that the commercial products being developed by our partners using our core technology are uniquely positioned in their markets."

Eden Research plc	www.edenresearch.com
Sir Ben Gill, Chairman	Tel: 01993 862 761
Clive Newitt, Managing Director
Alex Abrey, Chief Financial Officer
W H Ireland Limited	Tel: 0117 945 3471
John Wakefield Mike Coe
Walbrook PR Ltd	Tel: 020 7933 8780 or eden@walbrookpr.com
Paul McManus (Media Relations)	Mob: 07980 541 893
Paul Cornelius (Investor Relations)	Mob: 07827 879 496

Notes:

Eden has developed a terpene-based encapsulation technology which uses yeast cells to deliver a slow release of natural compounds for agricultural and non-agricultural uses.

Terpenes are natural compounds which function as defence mechanisms in many plant groups and are released in response to infection, attack by pests, stress or mechanical injury. Terpenes are already widely used in the food flavouring, cosmetic and pharmaceutical industries.

Historically, terpenes have had limited commercial use in the agrochemical sector due to their volatility, phytotoxicity and poor solubility. Eden's platform encapsulation technology provides a unique, environmentally friendly solution to these problems and enables terpenes to be used as effective, low-risk agrochemicals.

A key milestone for the business was reached in May 2013 when the three active substances used in the Company's lead product, 3AEY, were approved for use in plant protection products within the European Union.

This allows the actives to be used with Eden's encapsulation technology in any combination to create a range of agrochemical products for a variety of applications.

The next-generation encapsulation technology, licensed from University of Massachusetts Medical School ("UMMS") recently, provides significant additional benefits to the original system as it allows release to be controlled by environmental factors rather than relying solely upon the chemistry of the substances used. This means that there is more control over the timing of the release of the active compound being carried allowing for further reduction in chemicals applied whilst ensuring maximum effectiveness.

The UMMS license also significantly expands the potential use of the Eden technology in non-agricultural applications such as health and beauty, cosmetics and animal health.

For more information about Eden, please visit www.edenresearch.com 

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCBLGDILGDBGXR